{"nctId":"NCT00262301","briefTitle":"Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","startDateStruct":{"date":"2004-06"},"conditions":["Hereditary Angioedema","Angioneurotic Edema","Genetic Disorders"],"count":75,"armGroups":[{"label":"100 IU/kg \"rhC1INH\"","type":"EXPERIMENTAL","interventionNames":["Drug: recombinant human C1 inhibitor"]},{"label":"Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"recombinant human C1 inhibitor","otherNames":["\"rhC1INH\"","Ruconest","conestat alfa"]},{"name":"Placebo","otherNames":["saline","physiological salt solution"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clear clinical and laboratory diagnosis of HAE\n* Baseline plasma level of functional C1INH of less than 50% of normal\n* Evidence for exacerbation or development of a severe abdominal, oro-facial/ pharyngeal/ laryngeal, genito-urinary and/or peripheral HAE attack\n\nExclusion Criteria:\n\n* Acquired angioedema\n* Pregnancy or breastfeeding\n* Participation in another clinical study within prior 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Beginning of Relief of Symptoms","description":"The time to beginning of relief of symptoms has been assessed by using a patient-reported visual analogue scale (\"VAS\") ranging from 0 mm (no symptoms at all) to 100 mm (extremely disabling). Time to beginning of relief of symptoms at the location that showed first \"VAS\" score decrease of at least 20 mm from baseline score (t= 0 min) to the next assessment time-point). Assessment time-points were taken on pre-scheduled time-points after drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to beginning of relief has been calculated as median time, by using the exact time-points on which each assessment was performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"508","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Minimal Symptoms","description":"the time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale (\"VAS\") score. Symptoms were said to be minimal when the \"VAS\" score at all locations was below 20 mm. Assessment time-points were: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to minimal symptoms has been calculated by using the exact time-points on which each assessment was performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"480","spread":null},{"groupId":"OG001","value":"1440","spread":null},{"groupId":"OG002","value":"241","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["headache","nausea","pain","menstrual disorder","scrotal swelling"]}}}